Han All Pharmaceutical Co., Ltd. (009420.KS) Acquires Global Rights To Nautilus Biotech's Protein Engineering Technology For Developing Novel Oral And Injectable Therapeutic Proteins  
6/29/2009 1:49:11 PM

SEOUL, KOREA, June 24, 2009: HanAll Pharmaceutical Co., Ltd. announced that the company has been awarded global and exclusive ownership to all patents, data and documentation related to Nautilus Biotech’s high-speed throughput protein engineering technology and products. With only a small number of companies working in this area, this positions HanAll as a leader in the development of proprietary and novel protein therapeutics.